← All organizations
Ono Pharmaceuticals
Also known as: Clinical Department, Ono Pharmaceutical Co. Ltd | Clinical Development, ONO Pharma UK, Ltd | Ono Pharmaceutial Co., Ltd | ONO Pharmaceutical Co. | Ono Pharmaceutical Co. Ltd | Ono Pharmaceutical Co. LtTd. | Ono pharmaceutical Korea | Ono Pharma UK | Ono Pharma USA Inc
Highest phase reached
Phase 4
First clinical trial
Dec 1, 1996Last known activity
Nov 30, 2025
Timeline
1710s
- Jan 1, 1717
Ono Pharmaceuticals— Founded
2020s
- Apr 29, 2024
Deciphera Pharmaceuticals LLC— Acquired
Drugs by trial phase (111 distinct, 204 trials)
Phase 4 (4 own, 0 via acquisition)
Phase 3 (30 own, 10 via acquisition)
Phase 2 (29 own, 6 via acquisition)
Phase 1 (26 own, 6 via acquisition)
Indications
Studied for
- Acromegaly
- Acute Disease
- Acute Lung Injury
- Alzheimer Disease
- Amyotrophic Lateral Sclerosis
- Arthritis
- Arthritis, Juvenile
- Arthritis, Rheumatoid
- Asthma
- Blood Coagulation Disorders
- Bone Diseases
- Bone Diseases, Metabolic
- Brain Neoplasms
- Breast Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Chronic Disease
- Colorectal Neoplasms
- Communicable Diseases
- Coronary Artery Disease
- Coronary Disease
- Depression
- Depressive Disorder
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diarrhea
- Disease
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Glaucoma
- Glaucoma, Open-Angle
- Glioblastoma
- Hemostatic Disorders
- Hypersensitivity
- Hypertension
- Infections
- Irritable Bowel Syndrome
- Kidney Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Liver Diseases
- Lung Injury
- Lung Neoplasms
- Lymphoma
- Lymphoma, Non-Hodgkin
- Major Depressive Disorder
- Melanoma
- Mesothelioma
- Microsatellite Instability
- Motor Neuron Disease
- Mouth Neoplasms
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Myelodysplastic Syndromes
- Myocardial Ischemia
- Neoplasms
- Neurodegenerative Diseases
- Ocular Hypertension
- Osteoarthritis
- Osteoarthritis, Knee
- Osteoporosis
- Osteoporosis, Postmenopausal
- Pancreatic Neoplasms
- Parkinson Disease
- Pneumonia
- Preleukemia
- Rectal Neoplasms
- Recurrence
- Respiratory Distress Syndrome
- Respiratory Insufficiency
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Seasonal
- Sclerosis
- Sinusitis
- Small Cell Lung Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Stomach Neoplasms
- Stroke
- Syndrome
- Systemic Inflammatory Response Syndrome
- Tachycardia
- Thrombocytopenia
- Thromboembolism
- Urinary Bladder, Overactive
- Venous Thromboembolism
- Wounds and Injuries
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (50)
- NCT07104032Lead sponsorPhase 3Nov 30, 2025
- NCT07198087OfficialPhase 1Oct 1, 2025
- NCT07198087Lead sponsorPhase 1Oct 1, 2025
- NCT06936943Lead sponsorPhase 2Sep 30, 2025
- NCT06936943OfficialPhase 2Sep 30, 2025
- NCT06948448Lead sponsorPhase 2Jul 31, 2025
- NCT06948448OfficialPhase 2Jul 31, 2025
- NCT06881836OfficialPhase 2Apr 24, 2025
- NCT06881836Lead sponsorPhase 2Apr 24, 2025
- NCT06816108Lead sponsorPhase 1Apr 21, 2025
- NCT06816108OfficialPhase 1Apr 21, 2025
- NCT06752590OfficialPhase 2Mar 31, 2025
- NCT06752603Lead sponsorPhase 2Mar 31, 2025
- NCT06752603OfficialPhase 2Mar 31, 2025
- NCT06752590Lead sponsorPhase 2Mar 31, 2025
Details
- Founded
- Osaka, JP Jan 1, 1717
- Last known activity
- Nov 30, 2025
Notes
1998-ONO PHARMA UK LTD. and ONO PHARMA USA, INC. were established https://www.ono.co.jp/eng/about/history.html